Literature DB >> 19231384

Differential effects of natriuretic peptides on arterial and venous coronary artery bypass conduits.

Hao G Nguyen1, Amit Korach, Chey Collura, Benjamin R Eskenazi, Joseph A Vita, Oz M Shapira.   

Abstract

BACKGROUND: Arterial grafts have patency rates superior to venous grafts in patients undergoing coronary bypass grafting surgery. Natriuretic peptides play a major role in vascular homeostasis. We hypothesized that natriuretic peptides might have different effects on arterial and venous conduits.
METHODS: The relaxation responses and tissue levels of cyclic guanosine monophosphate (cGMP) after exposure to atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide were assessed in segments of internal mammary artery, radial artery, and saphenous vein obtained from the same patients at the time of bypass surgery (n = 12). Natriuretic peptide receptor (NPR) expression was assessed using immunohistochemistry and Western blotting.
RESULTS: Relaxation of the internal mammary artery and radial artery to all the natriuretic peptides were similar, and greater than that of saphenous vein, correlating with increased tissue levels of cGMP in both arterial conduits. Relaxation responses to all three natriuretic peptides were nearly abolished in the presence of LY83583, an inhibitor of guanylyl cyclase. Exposure of the conduits to N(G)-Nitro-L-arginine methyl ester (nitric oxide synthase inhibitor) resulted in a modest but significant blunting of the relaxation responses. Expression of NPR(A), NPR(B) and NPR(C)was strong in the endothelium and vascular smooth muscle layer of the internal mammary artery and radial artery, and was significantly less in saphenous vein.
CONCLUSIONS: Natriuretic peptides are potent vasodilators of the internal mammary artery and radial artery but not the saphenous vein. The relaxation response is mediated through guanylyl cyclase and nitric oxide synthase. These observations may provide additional insight into the mechanisms that account for superior patency of arterial conduits.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19231384      PMCID: PMC2696162          DOI: 10.1016/j.athoracsur.2008.12.004

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  25 in total

1.  Mechanism of Aurora-B degradation and its dependency on intact KEN and A-boxes: identification of an aneuploidy-promoting property.

Authors:  Hao G Nguyen; Dharmaraj Chinnappan; Takeshi Urano; Katya Ravid
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

Review 2.  Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.

Authors:  Lincoln R Potter; Sarah Abbey-Hosch; Deborah M Dickey
Journal:  Endocr Rev       Date:  2005-11-16       Impact factor: 19.871

3.  C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression.

Authors:  Ramona S Scotland; Marc Cohen; Paul Foster; Matthew Lovell; Anthony Mathur; Amrita Ahluwalia; Adrian J Hobbs
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-22       Impact factor: 11.205

4.  Nitric oxide and C-type atrial natriuretic peptide stimulate primary aortic smooth muscle cell migration via a cGMP-dependent mechanism: relationship to microfilament dissociation and altered cell morphology.

Authors:  C Brown; X Pan; A Hassid
Journal:  Circ Res       Date:  1999-04-02       Impact factor: 17.367

Review 5.  Natriuretic peptide receptor-C signaling and regulation.

Authors:  Madhu B Anand-Srivastava
Journal:  Peptides       Date:  2005-04-08       Impact factor: 3.750

Review 6.  Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention.

Authors:  J G Motwani; E J Topol
Journal:  Circulation       Date:  1998-03-10       Impact factor: 29.690

7.  C-Type natriuretic peptide and natriuretic peptide receptors are expressed by smooth muscle cells in the neointima after percutaneous coronary intervention.

Authors:  Takahiko Naruko; Akira Itoh; Kazuo Haze; Shoichi Ehara; Hiroko Fukushima; Yoshimi Sugama; Nobuyuki Shirai; Yoshihiro Ikura; Masahiko Ohsawa; Makiko Ueda
Journal:  Atherosclerosis       Date:  2005-03-05       Impact factor: 5.162

8.  Atrial natriuretic peptide-induced release of cyclic guanosine monophosphate by coronary bypass grafts.

Authors:  J Bonatti; W Dichtl; E A Dworzak; H Antretter; F Unger; B Puschendorf; O E Dapunt
Journal:  Ann Thorac Surg       Date:  1998-06       Impact factor: 4.330

9.  Natriuretic peptide-augmented induction of nitric oxide synthase through cyclic guanosine 3',5'-monophosphate elevation in vascular smooth muscle cells.

Authors:  T Marumo; T Nakaki; K Hishikawa; J Hirahashi; H Suzuki; R Kato; T Saruta
Journal:  Endocrinology       Date:  1995-05       Impact factor: 4.736

10.  Role of nitric oxide on cardiac hormone secretion: effect of NG-nitro-L-arginine methyl ester on atrial natriuretic peptide and brain natriuretic peptide release.

Authors:  H Leskinen; O Vuolteenaho; J Leppäluoto; H Ruskoaho
Journal:  Endocrinology       Date:  1995-03       Impact factor: 4.736

View more
  2 in total

Review 1.  Thirty-year experience with bilateral internal thoracic artery grafting: where have we been and where are we going?

Authors:  Paul Kurlansky
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

2.  Co-Culture of Primary Human Coronary Artery and Internal Thoracic Artery Endothelial Cells Results in Mutually Beneficial Paracrine Interactions.

Authors:  Daria Shishkova; Victoria Markova; Maxim Sinitsky; Anna Tsepokina; Alexey Frolov; Nikita Zagorodnikov; Leo Bogdanov; Anton Kutikhin
Journal:  Int J Mol Sci       Date:  2020-10-28       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.